The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Be at least 18 years of age;
Provide written informed consent;
Patients with NK Stage 2 (PED) or Stage 3 (corneal ulcer);
Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to NK;
Anticipated need to use therapeutic contact lenses or contact lens wear for refractive correction during the 28-days Treatment Period in the eye(s) with NK;
Be a woman of childbearing potential who is not using an acceptable means of birth control;